Oral semaglutide in a tablet intended for treatment of adults with type 2 diabetes. Credit: Novo Nordisk A/S.

Novo Nordisk has reported positive results from the Phase IIIb SUSTAIN 9 clinical trial evaluating Ozempic (semaglutide) when added to an SGLT-2 inhibitor (SGLT-2i) in adults living with type 2 diabetes.

Ozempic is a once-weekly human glucagon-like peptide-1 (GLP-1) analogue intended to be used as an adjunct to diet and exercise for improving glycaemic control in type 2 diabetes patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The trial met its primary endpoint with a statistically significant and superior reduction of 1.5% in HbA1c, compared to 0.1% with placebo, both given in combination with SGLT2-i therapy.

A secondary endpoint analysis revealed statistically significant and superior decrease in body weight of 4.7kg, which was found to be 0.9kg in placebo group.

“The results from SUSTAIN 9 demonstrated that Ozempic in combination with an SGLT-2 inhibitor is effective in lowering blood sugar and reducing body weight.”

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: “The results from SUSTAIN 9 demonstrated that Ozempic in combination with an SGLT-2 inhibitor is effective in lowering blood sugar and reducing body weight.

“These data further reinforce the results from across the SUSTAIN clinical development programme and the benefits of Ozempic that clinicians from many countries are already seeing in their day-to-day practices.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The double-blind, randomised, parallel-group SUSTAIN 9 trial evaluated the safety and efficacy of 1mg Ozempic with SGLT-2i therapy, as monotherapy or in combination with metformin or sulfonylurea, over 30 weeks.

Primary outcome of the Phase IIIb study was a change in HbA1c from baseline at week 30.

SUSTAIN 9 is part of Ozempic’s SUSTAIN clinical development programme involving ten Phase III trials, including a cardiovascular outcomes study in type 2 diabetes patients with high cardiovascular risk.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact